Table 3 Meta-analysis of cohorts for the association of suggestive SNPs with the comorbid disease in T2D patients.
a CVD | Discovery 390/981 | Replication | Meta-analysis 772/2012 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prevend 39/143 | Rotterdam 343/888 | |||||||||||
SNP | Chr: Position | Risk Allele | MAF | HR (95%CI) | P val | HR (95%CI) | P Val | HR (95%CI) | P Val | P HR (95%CI) | P Val | P Val het |
rs1288331 | 1:53,403,637 | G | 0.42 | 1.34 (1.17–1.54) | 2.49 × 10–5 | 1.43 (0.91–2.24) | 0.13 | 1.01 (0.86–1.17) | 0.90 | 1.21 (0.95–1.53) | 0.11 | 0.01 |
rs7553128 | 1:53,384,490 | A | 0.21 | 1.45 (1.21–1.72) | 5.17 × 10–5 | 2.14 (0.70–6.54) | 0.18 | 0.87 (0.72–1.05) | 0.16 | 1.22 (0.77–1.92) | 0.39 | 0.00 |
rs13415601 | 2:210,788,369 | A | 0.07 | 0.54 (0.41–0.72) | 2.76 × 10–5 | na | – | 0.88 (0.67–1.15) | 0.35 | 0.69 (0.43–1.10) | 0.12 | 0.01 |
b Chronic eye disease | Discovery 182/1124 | Replication | Meta-analysis 505/1974 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prevend | Rotterdam 323/850 | |||||||||||
SNP | Chr: Positon | Risk Allele | MAF | HR (95%CI) | P val | HR (95%CI) | P Val | HR (95%CI) | P Val | P HR (95% CI) | P Val | P Val het |
rs10464834 | 8:97,640,442 | A | 0.16 | 2.19 (1.51–3.19) | 8.55 × 10–5 | na | – | 1.05 (0.80–1.37) | 0.69 | 1.50 (0.73–3.09) | 0.26 | 0.00 |
rs11036364 | 11:5,205,580 | A | 0.42 | 0.63 (0.50–0.78) | 4.02 × 10–5 | na | – | 1.08 (0.92–1.26) | 0.30 | 0.83 (0.48–1.41) | 0.49 | 0.00 |
rs1870849 | 16:81,380,132 | A | 0.08 | 1.87 (1.36–2.55) | 1.02 × 10–5 | na | – | 1.40 (0.97–2.00) | 0.06 | 1.64 (1.23–2.17) | 0.00 | 0.23 |
rs8051326 | 16:81,380,213 | G | 0.08 | 1.89 (1.35–2.63) | 1.15 × 10–5 | na | – | 1.40 (0.97–2.00) | 0.06 | 1.64 (1.22–2.19) | 0.00 | 0.23 |
c Cancer | Discovery 155/1119 | Replication | Meta-analysis 444/2157 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prevend 22/141 | Rotterdam 267/897 | |||||||||||
SNP | Chr: Position | Risk Allele | MAF | HR (95%CI) | P val | HR (95%CI) | P Val | HR (95%CI) | P Val | P HR (95%CI) | P Val | P Val het |
rs4576663 | 1:190,123,195 | A | 0.09 | 2.43 (1.60–3.66) | 2.66 × 10–5 | 1.64 (0.05–45.92) | 0.77 | 0.82 (0.52–1.30) | 0.41 | 1.43 (0.54–3.77) | 0.45 | 0.00 |
rs2305948 | 4:55,979,558 | A | 0.13 | 1.90 (1.39–2.61) | 3.97 × 10–5 | 0.29 (2.71–33.11) | 0.62 | 0.99 (0.72–1.37) | 0.97 | 1.34 (0.73–2.47 | 0.34 | 0.01 |
rs1882149 | 12:119,922,525 | A | 0.15 | 1.87 (1.39–2.50) | 5.68 × 10–5 | 0.69 (0.01–39.68) | 0.86 | 0.85 (0.64–1.13) | 0.27 | 1.24 (0.60–2.56) | 0.56 | 0.00 |
d Chronic kidney disease | Discovery 13/1159 | Replication | Meta-analysis 87/1950 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prevend | Rotterdam 74/791 | |||||||||||
SNP | Chr: Position | Risk Allele | MAF | HR (95%CI) | P val | HR (95%CI) | P Val | HR (95%CI) | P Val | P HR (95% CI) | P Val | P Val het |
rs742829 | 6:151,300,463 | G | 0.46 | 7.76 (2.86–21.11) | 6.39 × 10–5 | na | – | 1.30 (0.85–2.00) | 0.21 | 3.00 (0.52–17.1) | 0.21 | 0.00 |
rs249 | 8:19,855,286 | G | 0.30 | 5.16 (2.26–11.75) | 8.09 × 10–5 | na | – | 0.79 (0.38–1.63) | 0.53 | 2.00 (0.32–12.51) | 0.45 | 0.00 |
rs640090 | 10:95,382,575 | G | 0.15 | 9.49 (3.23–27.91) | 4.65 × 10–5 | na | – | 2.31 (0.29–17.93) | 0.42 | 6.20 (1.74–22.08) | 0.00 | 0.23 |
rs4281621 | 14:61,025,684 | G | 0.15 | 11.79 (4.34–32.07) | 1.63 × 10–6 | na | – | 2.29 (0.71–7.38) | 0.16 | 5.35 (1.07–26.65) | 0.04 | 0.03 |
rs1110192 | 14:61,061,727 | A | 0.19 | 15.64 (5.01–48.76) | 1.89 × 10–6 | na | – | 2.41 (0.75–7.72) | 0.13 | 6.17 (0.99–38.47) | 0.05 | 0.02 |
rs7159886 | 14:61,030,897 | G | 0.15 | 11.04 (3.34–36.48) | 9.35 × 10–5 | na | – | 2.14 (0.66–6.88) | 0.19 | 4.84 (0.97–24.09) | 0.05 | 0.05 |
